Fresenius Medical Care AG & Co. KGaA (Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world’s largest provider of dialysis products and services, yesterday introduced the 2008T, a smart-platform dialysis system featuring Fresenius Clinical Data Exchange (CDX) software, at the American Society of Nephrology’s 43rd Annual Meeting and Scientific Exposition in Denver, Colorado. The groundbreaking technology is the first fully integrated dialysis therapy and management information system on the market and was developed to help physicians and clinic operators adjust to the new bundled payment environment due to take effect in the United States in January 2011. Available immediately, the 2008T currently is scheduled to be marketed in North America and is cleared for use in the USA and Canada by the U.S. Food and Drug Administration and Health Canada.

The 2008T combines the company’s most advanced hemodialysis delivery system with Fresenius Clinical Data Exchange (CDX) to provide caregivers, for the first time, chairside access to both dialysis treatment and medical information system (MIS) data to facilitate real-time adjustments to therapy and care plans. The platform accommodates MIS software from third-party vendors as well as the company’s proprietary systems, providing immediate access to all dialysis treatment and clinical trending data traditionally held in multiple locations. This integrated approach streamlines workflow and maximizes data collection for comprehensive billing.

The 2008T was developed in close association with the Renal Research Institute, one of the pre-eminent research institutions in the United States focused on improving the clinical care and quality of life of patients with chronic kidney disease.

The PDF version of this news can be downloaded <link file:1441 - download "Initiates file download">here</link>.

***

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,716 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 210,191 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. 

***